Cellectis (CLLS) Share-based Compensation Growth (1y) (2016 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Share-based Compensation Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -7.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -8.89% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -22.43% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -4.01% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 78.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 78.55% |
| Mar 31, 2026 | 70.39% |
| Dec 31, 2025 | 154.52% |
| Sep 30, 2025 | -183.04% |
| Jun 30, 2025 | 54.46% |
| Mar 31, 2025 | 10.03% |
| Dec 31, 2024 | -80.87% |
| Sep 30, 2024 | 99.98% |
| Jun 30, 2024 | -49.54% |
| Mar 31, 2024 | -45.25% |
| Dec 31, 2023 | 1,094.06% |
| Sep 30, 2023 | -299.62% |
| Jun 30, 2023 | -18.20% |
| Mar 31, 2023 | -30.05% |
| Dec 31, 2022 | -79.98% |
| Sep 30, 2022 | -76.01% |
| Jun 30, 2022 | -49.60% |
| Mar 31, 2022 | 7,620.00% |
| Dec 31, 2021 | 169.53% |
| Sep 30, 2021 | 63.86% |